TALEN

TALEN3-ttn.2

ID
ZDB-TALEN-190405-1
Name
TALEN3-ttn.2
Previous Names
None
Target
Target Sequence 1
5' - TGTGGAGCAACCATGTTCAAAG - 3'
Target Sequence 2
5' - AGGAAATGAATATATA - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
vcc14 ttn.2
Expression
Gene expression in Wild Types + TALEN3-ttn.2
No data available
Phenotype
Phenotype resulting from TALEN3-ttn.2
No data available
Phenotype of all Fish created by or utilizing TALEN3-ttn.2
Phenotype Fish Conditions Figures
myocardium cytosol ab1-myom labeling mislocalised, abnormal ttn.2vcc14/vcc14 standard conditions Fig. 2 from Huttner et al., 2018
heart edematous, abnormal ttn.2vcc14/vcc14 standard conditions Fig. 2 from Huttner et al., 2018
myocardium sarcomere organization decreased process quality, abnormal ttn.2vcc14/vcc14 standard conditions Fig. 2 from Huttner et al., 2018
cardiac ventricle heart contraction decreased process quality, abnormal ttn.2vcc14/vcc14 standard conditions Fig. 2 from Huttner et al., 2018
myocardium Z disc disorganized, abnormal ttn.2vcc14/vcc14 standard conditions Fig. 2 from Huttner et al., 2018
myocardium cytosol ab1-myom labeling increased distribution, abnormal ttn.2vcc14/vcc14 standard conditions Fig. 2 from Huttner et al., 2018
blood circulation decreased occurrence, abnormal ttn.2vcc14/vcc14 standard conditions Fig. 2 from Huttner et al., 2018
whole organism lethal (sensu genetics), abnormal ttn.2vcc14/vcc14 standard conditions Fig. 2 from Huttner et al., 2018
atrium heart contraction decreased process quality, abnormal ttn.2vcc14/vcc14 standard conditions Fig. 2 from Huttner et al., 2018
cardiac ventricle heart contraction decreased occurrence, abnormal ttn.2vcc14/+ chemical treatment by environment: phenylhydrazine Fig. 5 from Huttner et al., 2018
regulation of heart contraction decreased occurrence, abnormal ttn.2vcc14/+ chemical treatment by environment: phenylhydrazine Fig. 5 from Huttner et al., 2018
cardiac ventricle increased size, abnormal ttn.2vcc14/+ chemical treatment by environment: phenylhydrazine Fig. 5 from Huttner et al., 2018
heart nppa expression increased amount, abnormal ttn.2vcc14/+ chemical treatment by environment: phenylhydrazine Fig. 5 from Huttner et al., 2018
atrium increased area, exacerbated ttn.2vcc14/+ chemical treatment by environment: phenylhydrazine Fig. 5 from Huttner et al., 2018
cardiac ventricle heart contraction decreased occurrence, abnormal ttn.2vcc14/+ control Fig. 5 from Huttner et al., 2018
male organism heart contraction decreased process quality, abnormal ttn.2vcc14/+ standard conditions Fig. 3 from Huttner et al., 2018
female organism atrium increased area, abnormal ttn.2vcc14/+ standard conditions Fig. 3 from Huttner et al., 2018
female organism decreased weight, abnormal ttn.2vcc14/+ standard conditions Fig. 3 from Huttner et al., 2018
heart nppb expression increased amount, abnormal ttn.2vcc14/+ chemical treatment by environment: phenylhydrazine Fig. 5 from Huttner et al., 2018
blood hemoglobin decreased amount, abnormal ttn.2vcc14/+ chemical treatment by environment: phenylhydrazine Fig. 5 from Huttner et al., 2018
heart nppa expression decreased amount, abnormal ttn.2vcc14/+ control Fig. 5 from Huttner et al., 2018
atrial myocardium has fewer parts of type atrial myocardium sarcomere, abnormal ttn.2vcc14/+ standard conditions Fig. 4 from Huttner et al., 2018
female organism heart contraction decreased process quality, abnormal ttn.2vcc14/+ standard conditions Fig. 3 from Huttner et al., 2018
ventricular myocardium has fewer parts of type ventricular myocardium sarcomere, abnormal ttn.2vcc14/+ standard conditions Fig. 4 from Huttner et al., 2018
Citations